Showing 2481-2490 of 5644 results for "".
- Gemini Therapeutics Debuts as Publicly Traded Company Focused on Age-Related Macular Degenerationhttps://modernod.com/news/gemini-therapeutics-debuts-as-publicly-traded-company-focused-on-age-related-macular-degeneration/2478841/Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Gemini Therapeutics, the resulting combined company, will commence trading its shares today on the Nasdaq Global Market u
- GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non‑Human Primateshttps://modernod.com/news/gensight-biologics-announces-the-publication-in-communications-biology-of-the-proof-of-concept-for-gs030-drug-product-in-none28091human-primates/2478834/GenSight Biologics announced that the journal Communications Biology has published results from the study of GS030-Drug Product (GS030-DP) in non-human primates (NHP). The paper,* published in the January issue under the title “Optogenetic therapy: high spatiotemporal resolution and
- Aldeyra Therapeutics Announces Phase 3 TRANQUILITY Dry Eye Disease Trial Designhttps://modernod.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/Aldeyra Therapeutics announced the finalization of the design of the phase 3 TRANQUILITY trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. Consistent with previously announced results from the run-in cohort of TRANQUILITY, ocular redness over 90 minutes in a dry
- GSK, CureVac Partner to Develop mRNA Vaccines for COVID-19 Variantshttps://modernod.com/news/gsk-curevac-partner-to-develop-mrna-vaccines-for-covid-19-variants/2478831/GlaxoSmithKline entered into a new collaboration with CureVac to develop a multi-valent mRNA candidate vaccine to address multiple emerging variants of COVID-19, the companies announced Wednesday. “We believe that next-generation vaccines will be crucial in the continued fight against COVID
- Jazz to Buy Cannabinoid Drugmaker GW Pharma in $7.2-Billion Dealhttps://modernod.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/Jazz Pharmaceuticals entered into a definitive agreement to acquire GW Pharmaceuticals for $220 per share, or a total consideration of $7.2 billion, adding the latter’s cannabinoid product platform, including Epidiolex (cannabidiol), to its neuroscience pipeline, the companies announced Wed
- NeuroVision Imaging Receives Funding From the ADDF to Develop Biomarkers to Diagnose Alzheimer’s and Related Dementiashttps://modernod.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/NeuroVision Imaging announced it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders. “Many of the existing diagnostic
- Alcon Canada Introduces the Clareon IOL with the AutonoMe Preloaded Intraocular Lens Delivery Systemhttps://modernod.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/Alcon has announced a nationwide launch of the Clareon IOL with the AutonoMe delivery system in Canada. AutonoMe is an automated, disposable, preloaded IOL delivery system that enables precise delivery of the IOL into the capsular bag in patients undergoing cataract surgery, according to
- MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2478795/MeiraGTx Holdings announced that the FDA has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. ACHM is an inherited retinal disease that severely limits a per
- Keeler Partners With Merakris Therapeutics, Developer of Biological Barrier Grafthttps://modernod.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/Keeler has announced its partnership with Merakris Therapeutics, which is developing commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Terms of the deal were not disclosed. “We are excited. This partnership accelera
- Market Scope: Refractive Surgery to Grow 9.6% a Year Through 2025, Despite COVID-19https://modernod.com/news/market-scope-refractive-surgery-to-grow-9-6-a-year-through-2025-despite-covid-19/2478774/Expanding use of products to treat refractive error will increase the role of devices and surgical procedures in the refractive landscape, according to a new Market Scope report. Globally, over 2.3 billion people require vision correction and have access to ophthalmic care. Global demand f